Ad
related to: targeted therapy for hodgkin's lymphoma life expectancydiscoverpanel.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
The evidence is very uncertain about the effect of Nivolumab for patients with a Hodgkin's lymphoma e.g. on the overall survival. [50] Increased age is an adverse risk factor for Hodgkin lymphoma, but in general elderly people (≥ 60 years of age) without major comorbidities are sufficiently fit to tolerate therapy with curative intent.
As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. [citation needed] It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. [1]
Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy. [6] Co-targeted therapy involves the use of one or more therapeutics aimed at multiple targets, for example PI3K and MEK, in an attempt to generate a synergistic response [5] and prevent the development of drug resistance. [7] [8]
Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...
Because of the prolonged survival, which was typically about 10 years in past decades, but which can extend to a normal life expectancy, the prevalence (number of people living with the disease) is much higher than the incidence (new diagnoses). [2] CLL is the most common type of leukemia in the UK, accounting for 38% of all leukemia cases.
BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group [1] used for patients in Stages > II or early (IA or IB) with unfavorable risk factors. [2] Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21. [3]
MOPP is a combination chemotherapy regimen used to treat Hodgkin lymphoma. The acronym is derived from the component drugs of the regimen: ustargen (also known as mechlorethamine, chlormethine, mustine, nitrogen mustard, or MSD) ncovin (also known as Vincristine or VCR) rocarbazine (also known as Matulane or Natulan)
Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. [2] Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R , ABL , c-KIT , FLT3 , and PDGFR-β .
Ad
related to: targeted therapy for hodgkin's lymphoma life expectancydiscoverpanel.com has been visited by 10K+ users in the past month